After a long evaluation period, which included approximately 20 treatments of sarcoids and melanomas in horses, the hospital group-operating across the world-has agreed to gradually integrate TSE into its treatment offerings. This decision comes after witnessing the potential of the vetIQure™ TSE technology in addressing challenging equine tumors.

The initial transaction includes a vetIQure™ system, comprising the vetIQure device and its specialized treatment kits. This marks the beginning of a long-term collaboration aimed at expanding the use of TSE in equine oncology.
 

"We are very pleased to have concluded an extensive evaluation with a global equine hospital group that owns and operates hospitals in Scandinavia, many European countries, North America, and New Zealand," says Mohan Frick, CEO of Scandinavian ChemoTech.

Scandinavian ChemoTech continues to expand its footprint in the veterinary sector, reinforcing its commitment to improving cancer treatments for both animals and humans. This latest collaboration further underscores the growing demand for innovative and effective oncology solutions in veterinary medicine.

In addition to publicly announced orders, ChemoTech and its subsidiaries regularly receive undisclosed orders, as these are considered a natural part of ongoing business operations and company development and are therefore not deemed to have an impact on the share price.